Donepezil/Glycopyrronium Bromide

多奈哌齐/格隆溴铵

Report date: 2022/09/06 14:06:19

Base Information

Drug NameDonepezil/Glycopyrronium Bromide
Drug Alias Name格隆溴铵/多奈哌齐Glycopyrronium Bromide/DonepezilGlycopyrronium Bromide+DonepezilDonepezil+glycopyrrolateDonepezil/glycopyrrolate +[7] 
ClassificationSmall molecules
Mechanisms of ActionAcetylcholinesterase inhibitorsMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptorAcetylcholinesterase
Therapy Area/IndicationsAlzheimer DiseaseLewy Body Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Donepezil HydrochlorideGlycopyrronium Bromide
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSio Gene Therapies IncQaam Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesQaam PharmaceuticalsSio Gene Therapies Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseLewy Body Disease

Other Information

ATC CodeN/A
Related LinksN/A